MedPath

Bezafibrate

Generic Name
Bezafibrate
Brand Names
Bezalip
Drug Type
Small Molecule
Chemical Formula
C19H20ClNO4
CAS Number
41859-67-0
Unique Ingredient Identifier
Y9449Q51XH
Background

Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

Indication

For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).

Associated Conditions
Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia, Primary Hypercholesterolemia, Type IIb hyperlipoproteinaemia

Bezafibrate Plus Berberine in Mixed Dyslipidemia

Phase 3
Completed
Conditions
Mixed Dyslipidemia
Interventions
First Posted Date
2015-09-14
Last Posted Date
2023-02-24
Lead Sponsor
University of Guadalajara
Target Recruit Count
36
Registration Number
NCT02548832
Locations
🇲🇽

Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico

BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study

Phase 2
Conditions
Bipolar Disorder
Depressive Episode
Interventions
First Posted Date
2015-06-25
Last Posted Date
2021-12-02
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
30
Registration Number
NCT02481245
Locations
🇺🇸

The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Bezafibrate in Mitochondrial Myopathy

Phase 2
Completed
Conditions
Mitochondrial Diseases
Interventions
First Posted Date
2015-03-25
Last Posted Date
2017-09-21
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Target Recruit Count
6
Registration Number
NCT02398201
Locations
🇬🇧

Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United Kingdom

Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction

Phase 4
Completed
Conditions
Acute Myocardial Infarction
Interventions
First Posted Date
2014-11-14
Last Posted Date
2014-11-14
Lead Sponsor
Instituto Mexicano del Seguro Social
Target Recruit Count
100
Registration Number
NCT02291796

Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Phase 3
Completed
Conditions
PBC
Interventions
Drug: placebo
First Posted Date
2012-08-01
Last Posted Date
2023-02-27
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
100
Registration Number
NCT01654731
Locations
🇫🇷

Hepatology department - Hopital Saint Antoine, Paris, France

The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)

Not Applicable
Completed
Conditions
X-linked Adrenoleukodystrophy
Adrenomyeloneuropathy
Interventions
First Posted Date
2010-07-19
Last Posted Date
2011-08-10
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
10
Registration Number
NCT01165060
Locations
🇳🇱

Academisch Medisch Centrum, Amsterdam, NH, Netherlands

Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects

Phase 2
Completed
Conditions
Carnitine Palmitoyltransferase II Deficiency
Very Long Chain Acyl Coa Dehydrogenase Deficiency
Interventions
Other: Placebo
First Posted Date
2009-09-24
Last Posted Date
2012-05-30
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
12
Registration Number
NCT00983788
Locations
🇩🇰

Neuromusculare Research Unit, Rigshospitalet, Copenhagen, Denmark

Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes

Phase 2
Completed
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2007-07-25
Last Posted Date
2009-05-13
Lead Sponsor
Zalicus
Target Recruit Count
150
Registration Number
NCT00506298
Locations
🇨🇦

Robarts Research Institute, London, Ontario, Canada

Bezafibrate Trial in CPT2 Deficiency

Phase 3
Conditions
Carnitine Palmitoyl Transferase 2 Deficiency
First Posted Date
2006-06-13
Last Posted Date
2007-04-09
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
12
Registration Number
NCT00336167
Locations
🇫🇷

Jean Paul Bonnefont, Paris, France

© Copyright 2025. All Rights Reserved by MedPath